Angelo DePalma, PhD

While researchers study new pain-killing pathways, the pharma industry tries drug combinations and alternative-delivery mechanisms By Angelo DePalma, PhD

Oncology drug development pipelines are overflowing, but the sky-high prices of these agents are turning reimbursement schemes, and the very practice of cancer medicine, on their heads

A fast-growing market supports more, and more comprehensive, data services

Spurred by some recent successful launches, and with hefty R&D funding commitments, the vaccine business is booming

Although human trials in the U.S. are still a novelty, developers are identifying both sources and protocols for conducting therapy